Drug Quality Screening Technology Recognized - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Quality Screening Technology Recognized


PharmaCheck, a portable tool designed to detect poor-quality medicines, has been selected by Scientific American as one of the magazine’s World Changing Ideas of 2013. The device was developed by researchers from Boston University (BU) in collaboration with the Promoting the Quality of Medicines (PQM) program of the US Pharmacopeial Convention (USP).

BU and USP scientists have spent the last two years honing the technology behind PharmaCheck into an inexpensive, portable tool capable of assessing active ingredients in medicines.

PharmaCheck uses a fluorescent probe tailored to bind to an active ingredient in a specific drug and a silicon-polymer testing chip that detects the amount of light the probe emits. Software translates that light reading into an estimate of active ingredient concentration. Monitoring that signal over time indicates the ingredient’s dissolution. Within minutes, a doctor, regulatory official or health worker can have critical insight about the quality of a medicine sample.

Since 2009, USP has been providing technical assistance to regulatory, quality control and health care personnel in developing countries via PQM as a central strategy in the fight against substandard and counterfeit medicines

In early 2014, BU researcher Muhammad Zaman, developer of the technology, will conduct field tests on PharmaCheck through USP’s Center for Pharmaceutical Advancement and Training (CePAT) in Accra, Ghana. The field tests will include probes for an antimalarial and an antibiotic drug.

 

Source: US Pharmacopeial Convention

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here